These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

550 related items for PubMed ID: 29361424

  • 1. Effect of Aromatase Inhibitor Therapy on Sleep and Activity Patterns in Early-stage Breast Cancer.
    Bhave MA, Speth KA, Kidwell KM, Lyden A, Alsamarraie C, Murphy SL, Henry NL.
    Clin Breast Cancer; 2018 Apr; 18(2):168-174.e2. PubMed ID: 29361424
    [Abstract] [Full Text] [Related]

  • 2. A prospective assessment of musculoskeletal toxicity and loss of grip strength in breast cancer patients receiving adjuvant aromatase inhibitors and tamoxifen, and relation with BMI.
    Lintermans A, Van Asten K, Wildiers H, Laenen A, Paridaens R, Weltens C, Verhaeghe J, Vanderschueren D, Smeets A, Van Limbergen E, Leunen K, Christiaens MR, Neven P.
    Breast Cancer Res Treat; 2014 Jul; 146(1):109-16. PubMed ID: 24816806
    [Abstract] [Full Text] [Related]

  • 3. Identification of tools to measure changes in musculoskeletal symptoms and physical functioning in women with breast cancer receiving aromatase inhibitors.
    Swenson KK, Nissen MJ, Henly SJ, Maybon L, Pupkes J, Zwicky K, Tsai ML, Shapiro AC.
    Oncol Nurs Forum; 2013 Nov; 40(6):549-57. PubMed ID: 24161633
    [Abstract] [Full Text] [Related]

  • 4. Prospective evaluation of finger two-point discrimination and carpal tunnel syndrome among women with breast cancer receiving adjuvant aromatase inhibitor therapy.
    Sheng JY, Blackford AL, Bardia A, Venkat R, Rosson G, Giles J, Hayes DF, Jeter SC, Zhang Z, Hayden J, Nguyen A, Storniolo AM, Tarpinian K, Henry NL, Stearns V.
    Breast Cancer Res Treat; 2019 Aug; 176(3):617-624. PubMed ID: 31079282
    [Abstract] [Full Text] [Related]

  • 5. Genetic variant in the osteoprotegerin gene is associated with aromatase inhibitor-related musculoskeletal toxicity in breast cancer patients.
    Lintermans A, Van Asten K, Jongen L, Van Brussel T, Laenen A, Verhaeghe J, Vanderschueren D, Lambrechts D, Neven P.
    Eur J Cancer; 2016 Mar; 56():31-36. PubMed ID: 26798969
    [Abstract] [Full Text] [Related]

  • 6. Changes in bone mineral density in women with breast cancer receiving aromatase inhibitor therapy.
    Kwan ML, Yao S, Laurent CA, Roh JM, Quesenberry CP, Kushi LH, Lo JC.
    Breast Cancer Res Treat; 2018 Apr; 168(2):523-530. PubMed ID: 29249058
    [Abstract] [Full Text] [Related]

  • 7. Effect of denosumab on low bone mineral density in postmenopausal Japanese women receiving adjuvant aromatase inhibitors for non-metastatic breast cancer: 24-month results.
    Nakatsukasa K, Koyama H, Ouchi Y, Ono H, Sakaguchi K, Matsuda T, Kato M, Ishikawa T, Yamada K, Yoshimura M, Koizumi K, Sakurai T, Shigematsu H, Takahashi S, Taira S, Suzuki M, Narui K, Niikura N, Hasegawa Y, Miura D, Konishi E, Taguchi T, Collaborative Study Group of Scientific Research of the Japanese Breast Cancer Society.
    Breast Cancer; 2019 Jan; 26(1):106-112. PubMed ID: 30054855
    [Abstract] [Full Text] [Related]

  • 8. Patient-reported symptoms and discontinuation of adjuvant aromatase inhibitor therapy.
    Kidwell KM, Harte SE, Hayes DF, Storniolo AM, Carpenter J, Flockhart DA, Stearns V, Clauw DJ, Williams DA, Henry NL.
    Cancer; 2014 Aug 15; 120(16):2403-11. PubMed ID: 24802413
    [Abstract] [Full Text] [Related]

  • 9. Patient-Reported Outcomes and Early Discontinuation in Aromatase Inhibitor-Treated Postmenopausal Women With Early Stage Breast Cancer.
    Kadakia KC, Snyder CF, Kidwell KM, Seewald NJ, Flockhart DA, Skaar TC, Desta Z, Rae JM, Otte JL, Carpenter JS, Storniolo AM, Hayes DF, Stearns V, Henry NL.
    Oncologist; 2016 May 15; 21(5):539-46. PubMed ID: 27009936
    [Abstract] [Full Text] [Related]

  • 10. Evolution in the risk of adverse events of adjuvant endocrine therapy in postmenopausal women with early-stage breast cancer.
    Reinhorn D, Yerushalmi R, Moore A, Desnoyers A, Saleh RR, Amir E, Goldvaser H.
    Breast Cancer Res Treat; 2020 Jul 15; 182(2):259-266. PubMed ID: 32488391
    [Abstract] [Full Text] [Related]

  • 11. Adjuvant aromatase inhibitor therapy in early breast cancer: what factors lead patients to discontinue treatment?
    Moscetti L, Agnese Fabbri M, Sperduti I, Fabrizio N, Frittelli P, Massari A, Pompei L, D'Auria G, Pofi E, Ruggeri EM.
    Tumori; 2015 Jul 15; 101(5):469-73. PubMed ID: 26108239
    [Abstract] [Full Text] [Related]

  • 12. The impact of endocrine therapy on sexual dysfunction in postmenopausal women with early stage breast cancer: encouraging results from a prospective study.
    Frechette D, Paquet L, Verma S, Clemons M, Wheatley-Price P, Gertler SZ, Song X, Graham N, Dent S.
    Breast Cancer Res Treat; 2013 Aug 15; 141(1):111-7. PubMed ID: 23942873
    [Abstract] [Full Text] [Related]

  • 13. A combination of hydroxytyrosol, omega-3 fatty acids and curcumin improves pain and inflammation among early stage breast cancer patients receiving adjuvant hormonal therapy: results of a pilot study.
    Martínez N, Herrera M, Frías L, Provencio M, Pérez-Carrión R, Díaz V, Morse M, Crespo MC.
    Clin Transl Oncol; 2019 Apr 15; 21(4):489-498. PubMed ID: 30293230
    [Abstract] [Full Text] [Related]

  • 14. Incidence and management of side effects associated with aromatase inhibitors in the adjuvant treatment of breast cancer in postmenopausal women.
    Mouridsen HT.
    Curr Med Res Opin; 2006 Aug 15; 22(8):1609-21. PubMed ID: 16870085
    [Abstract] [Full Text] [Related]

  • 15. Pilot study of acupuncture for the treatment of joint symptoms related to adjuvant aromatase inhibitor therapy in postmenopausal breast cancer patients.
    Crew KD, Capodice JL, Greenlee H, Apollo A, Jacobson JS, Raptis G, Blozie K, Sierra A, Hershman DL.
    J Cancer Surviv; 2007 Dec 15; 1(4):283-91. PubMed ID: 18648963
    [Abstract] [Full Text] [Related]

  • 16. Adherence to Adjuvant Endocrine Therapy in Women With Breast Cancer: A Prospective Observational Study in Japanese Women.
    Kuba S, Maeda S, Matsumoto M, Yamanouchi K, Yano H, Morita M, Sakimura C, Hatachi T, Tokai Y, Takatsuki M, Fujioka H, Hayashida N, Nagayasu T, Eguchi S.
    Clin Breast Cancer; 2018 Apr 15; 18(2):150-156. PubMed ID: 29290564
    [Abstract] [Full Text] [Related]

  • 17. Menopausal-type symptoms among breast cancer patients on aromatase inhibitor therapy.
    Gallicchio L, MacDonald R, Wood B, Rushovich E, Helzlsouer KJ.
    Climacteric; 2012 Aug 15; 15(4):339-49. PubMed ID: 22191462
    [Abstract] [Full Text] [Related]

  • 18. Insulin-like growth factor 1 and musculoskeletal pain among breast cancer patients on aromatase inhibitor therapy and women without a history of cancer.
    Gallicchio L, MacDonald R, Helzlsouer KJ.
    J Cancer Res Clin Oncol; 2013 May 15; 139(5):837-43. PubMed ID: 23408333
    [Abstract] [Full Text] [Related]

  • 19. Arthralgia induced by endocrine treatment for breast cancer: A prospective study of serum levels of insulin like growth factor-I, its binding protein and oestrogens.
    Lintermans A, Vanderschueren D, Verhaeghe J, Van Asten K, Jans I, Van Herck E, Laenen A, Paridaens R, Billen J, Pauwels S, Vermeersch P, Wildiers H, Christiaens MR, Neven P.
    Eur J Cancer; 2014 Nov 15; 50(17):2925-31. PubMed ID: 25304297
    [Abstract] [Full Text] [Related]

  • 20. Defining the aromatase inhibitor musculoskeletal syndrome: a prospective study.
    Singer O, Cigler T, Moore AB, Levine AB, Hentel K, Belfi L, Do HT, Mandl LA.
    Arthritis Care Res (Hoboken); 2012 Dec 15; 64(12):1910-8. PubMed ID: 22730307
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 28.